Old fashioned medicine bottle; Flickr image by dgroth

Domestic Policy -- National Institutes of Health (NIH)

As arguably the most important funder of domestic research and development (R&D), the U.S. government could play a huge role in improving access to medicine through creating opportunities for technology transfer to promote competition, and by implementing more progressive innovation policy.

Together, the National Institutes of Health are the world's leading funder of medical research and development. But most publicly-funded inventions are later commercialized exclusively by companies at a high monopolist price. Public Citizen and a coalition of health and humanitarian organizations are asking NIH to exercise its rights to license the medical technologies it supports to international organizations, to facilitate humanitarian use, competition, and expand access to medicines.

Learn more about humanitarian licensing

March 31, 2014 - Public Citizen's Global Access to Medicines Program letter to the editor of the New York Times: How Public Research Underpins Private Health Care (links to nytimes.com)

March, 2013 - Knowledge Ecology International: US government rights in patents: 2010-2012 (links to keionline.org)

November 2, 2012 - Nature: NIH asked to grant open license on HIV drug (links to blogs.nature.com)

November 19, 2010 - Comments on USPTO Proposal for Incentivizing Humanitarian Licensing of Patented Technologies, Joint Submission with Medicins Sans Frontieres, Oxfam America and Knowledge Ecology International

October 24, 2007 - Testimony of Robert Weissman, "The Role of Federally-Funded University Research in the Patent System" Before the Committee on the Judiciary

March 17, 2000 -  DHHS Secretary Donna Shalala to Representative Jan Schakowsky on WHO access to Federally Funded Patent Rights (links to keionline.org)

Back to Access to Medicines Home Page

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.